alterado para: A precision medicine platform using patient derived cancer cell models to predict drug efficacy.

Financiador

Organização

Publicações

Harnessing complex metabolic signatures to predict drug efficacy in ovarian cancer

Publication . Mendes, Ana Rita Soares; Isidro, Inês; Brito, Catarina

"Ovarian carcinoma (OvC) is the most lethal gynecologic malignancy. Unfortunately, most cases are diagnosed at the later stages of the disease, impacting patient outcomes, resulting in a 5-year survival rate of less than 40%. The standard-of-care (SOC) treatment consists of cytoreduction surgery for tumor debulking and adjuvant chemotherapy, comprising a combination of platinum (cisplatin or carboplatin) with taxane (paclitaxel or docetaxel) agents.(...)"

2022-07-04Tese de doutoramento

Acesso aberto

Ver mais

Entidade financiadora

Fundação para a Ciência e a Tecnologia

Número da atribuição

SFRH/BD/132163/2017